Transforming Immunotherapy for Hematologic Disorders
Treatment
Shielded Cell & Immunotherapy Pairs™
Using our cell-shielding technology and paired immunotherapies, we aim to develop curative therapies for patients with hematologic disorders.
Our proprietary immunotherapies deplete diseased cells, while our cell-shielding technology protects healthy cells.
Because the healthy cells are protected, the immunotherapy can be safely administered to boost engraftment or treat minimal residual disease.
{We have the ability to specifically edit a cell surface receptor to completely prevent antibody binding while keeping the receptor fully functional. Instead of removing a target entirely, this type of epitope editing has the potential to allow the shielding of any cell surface receptor, thereby enabling a much broader application of our technology.{
Lukas Jeker, M.D., Ph.D.
Founder, SVP Gene Editing
Technology
Cell Shielding
We use gene editing tools to insert novel protein variants into HSCs or other types of cells, allowing the cells to maintain their function while making them resistant to depletion by the paired immunotherapy.
Our shielding technology has proven to be effective in shielding cells from depletion mediated by antibodies, T-cell engagers, ADCs, and CAR-T cells.
{Our platform represents a fundamentally new approach to immunotherapy. Our therapies have the potential to offer a cure for patients with the most difficult to treat hematologic conditions.{
Thomas Fuchs
CEO